MAY 0 5 2004

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

form PTO-1449 (Modified)
(Use several sheets if necessary)

of

	COMPLETE IF KNOWN	
Application Number	10/825,068	
Confirmation Number	Unassigned	
Filing Date	April 14, 2004	
First Named Inventor	Liu and Villarete	
Group Art Unit	Unassigned	
Examiner Name	Unassigned	
Attorney Docket No.	55600-8014.US03	

					U.S. F	PATENT DOCUMENTS			
Examiner Initials*		Cite No.	U.S. Patent or Application Kind Cox NUMBER (if know.			Name of Patentee or Inventor of Cited Where Relevant Pa		Pages, Columns, Lines Where Relevant Passages Relevant Figures Appea	sor
BD 1			Imakawa	01/06/98					
١		2		5,906,816		Soos, et al.	05/25/99		
		3		5,958,402		Bazer, et al.	09/28/99		
		4		6,036,949		Richards, et al.	03/14/00		
		5		6,060,450		Soos, et al.	05/09/00		
		6		6,083,919		Johnson, <i>et al.</i>	07/04/00		
		7	2	2002/0013452	A1	Johnson, et al.	01/31/02		
		8		6,372,206		Soos, et al.	04/16/02		
		9		6,403,562		Johnson, et al.	06/11/02		
		10	2	2003/0012766	A1	Soos, et al.	01/16/03		
		11	2	2003/0049277	A1	Sokawa, et al.	03/13/03		
		12	2	2003/0130486	A1	Villarete, et al.	07/10/03		
		13	2	2003/0219405	A1	Sokawa, et al.	11/27/03		
		14	2004/0013643		A1	Mach	01/22/04		
	FOREIGN PATENT DOCUMENTS								
Examiner Cite Kind Code Initials* No. Office NUMBER (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	 				
BO	ĨŦ	15	PCT	WO 90/09806		Bazer, et al.	09/07/90	, <u>g</u>	
<u> </u>		16	PCT	WO 94/10313		Bazer, et al.	05/11/94	-	
		17	PCT	WO 96/28183		Soos, et al.	09/19/96		
		18	PCT	WO 97/33607		Soos, et al.	09/18/97		T
\		19	PCT	WO 00/78266		Pontzer, et al.	12/28/00		
	OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS								
	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Examiner Cite (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.		title of the item r(s), publisher, city	т					
80/	}	20	Alexenko, A.P., et al., Journal of Interferon and Cytokine Research 17:769-779, (1997).						
T	/	21	Bagaeva, L.V., et al., Journal of Neuroimmunology 137:109-116, (2003).						

EXAMINER	DATE CONSIDERED				
Brual Hur	4/13/06				
*EXAMINER: Initial if reference considered, whether or not criteria is in conform	Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not				
considered. Include copy of this form with next communication to	considered. Include copy of this form with next communication to application(s).				

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

..... i

Form PTO-1449 (Modified)
(Use several sheets if necessary)

	COMPLETE IF KNOWN				
	Application Number	10/825,068			
	Confirmation Number	Unassigned			
	Filing Date	April 14, 2004			
	First Named Inventor	Liu and Villarete			
Group Art Unit		Unassigned			
	Examiner Name	Unassigned			
	Attorney Docket No.	55600-8014.US03			

(Use several sheets if necessary)				Group Ar
				Examine
Sheet	2	of	2	Attorney

		OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	(
DOIT	22	Brennan, F.R., et al., J Med Microbiol 41:20-28, (1994).			
	23	Brod, S.A., et al., Journal of Neuroimmunology 58:61-69, (1995).			
	24	Brod, S.A., et al., Diabetologia <u>41</u> :1227-1232, (1998).			
	25	Brod, S.A., Journal of Interferon and Cytokine Research 19:841-852, (1999).			
	26	Carter, C.R.D., et al., Clin Exp Immunol 135:233-239, (2004).			
	27	Filion, L.G., et al., Clin Immunol 106:127-138, (2003).			
	28	Khan, O.A., et al., Mult Scler 4(2):63-69, (1998).			
	29	Losy, J., <i>et al.</i> , Folia Neuropathol <u>40</u> (4):173-175, (2002).			
	30	Makhlouf, K., et al., Journal of Neuroimmunology 119:145-149, (2001).			
	31	Moldovan, I.R., et al., Journal of Neuroimmunology 141:132-140, (2003).			
	32	Mujtaba, M.G., et al., Journal of Neuroimmunology 75:35-42, (1997).			
	33	Mujtaba, M.G., et al., Cell Immunol <u>186(2):94-102, (1998).</u>			
	34	Nakajima, A., et al., Journal of Interferon and Cytokine Research 22:397-402, (2002).			
	35	Petereit, H.F., et al., Journal of Neurological Sciences 206:209-214, (2003).			
	36	Pontzer, C.H., et al., Biochem Biophys <u>152(</u> 2):801-807, (1988).			
	37	Pontzer, C.H., Cancer Research <u>51</u> :5304-5307, (1991).			
	38	Soos, J.M., et al., Journal of Interferon and Cytokine Research 15:39-45, (1995).			
	39	Soos, J.M., et al., Journal of Neuroimmunology 75:43-50, (1997).			
	40	Soos, J.M., et al., The Journal of Immunology 169:2231-2235, (2002).			
	41	Tuohy, V.K., et al., Journal of Neuroimmunology 111:55-63, (2000).			
1	42	van Boxel-Dezaire, A.H.H., et al., Ann Neurol <u>45</u> :695-703, (1999).			
			\perp		

EXAMINER	DATE CONSIDERED
Bruce D. Hims	4/13/06
AFYAMINED. Initial if a Colores and ideal at the state of	The second secon

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).